HOME >> MEDICINE >> NEWS
Mount Sinai launches combination therapy trial to treat Relapsing-Remitting Multiple Sclerosis

New York, NY - Mount Sinai School of Medicine is the Clinical Coordinating Center for the first study to assess the effectiveness of combining two FDA approved medications as initial treatment for people with Relapsing Remitting Multiple Sclerosis. Sponsored by the National Institutes of Health National Institute of Neurological Disorders and Stroke (NIH-NINDS), the study, known as CombiRx, will determine if the combined use of each treatment reduces relapse rate when compared to either agent alone. Enrollment is currently underway at clinics across the United States and Canada.

According to study chairman, Fred D. Lublin, M.D., Saunders Family Professor of Neurology at Mount Sinai School of Medicine-Corinne Goldsmith Dickinson Center for Multiple Sclerosis, "This is a very important trial because, if effective, combination therapy will allow us to take advantage of these agents that have different and complementary mechanisms of action to slow or halt progression of MS."

An estimated 400,000 Americans suffer from MS, a chronic neurological disease that affects the central nervous system. MS is most commonly diagnosed in young adults. Relapsing-remitting MS, the most common form of new cases of the disease, is characterized by episodes of attacks of neurologic dysfunction, which occur over many years.

Approximately 130,000 MS patients are receiving either FDA-approved interferon beta-1a weekly (Avonex) or glatiramer acetate daily (Copaxone) to treat relapsing forms of MS. However, because these agents provide only a partial amelioration of the risk for additional attacks and development of disability, there is a major and continuing need for better therapies. As yet, there is no cure for MS.

CombiRx will determine whether the combination of these treatments is more effective than either treatment alone. This trial is unique among placebo controlled studies, in that none of the participants will receive placebo alone. All parti
'"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
11-Apr-2006


Page: 1 2

Related medicine news :

1. New breakthrough treatment for spinal cancer patients at Mount Sinai
2. Mount Sinai and EXACT Sciences announce study results on study stool DNA testing for colon cancer
3. Wiley to assume publication of Mount Sinai Journal of Medicine
4. Mount Sinai researcher finds drinking water safe to drink
5. The Mount Sinai Medical Center recognized for excellence in bariatric surgery
6. Mount Sinai Global Health Center receives $1M grant
7. Mount Sinai School of Medicine receives prestigious AAMC Grant for Chronic Illness Care education
8. Mount Sinai and YAI/NIPD Network join forces to further quality of care for people with autism
9. CNIC commits 5 million Euros to the Mount Sinai School of Medicine
10. Mount Sinai expands cutting-edge molecular testing
11. Mountain bikers are cautioned to ride with care - major injuries do happen

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/4/2020)... ... July 03, 2020 , ... ... featured in Biocompare’s latest content hub— Future Lab: COVID-19 R&D . , ... advancements, trends, news, and products within specific scientific niches. Since their launch four ...
(Date:7/2/2020)... ... 02, 2020 , ... Columbia Southern University (CSU), a leading ... to Eric Simmons of Temecula, California. , CSU’s occupational safety and health ... master’s degree in occupational safety and health from the university, is the corporate ...
(Date:7/1/2020)... ... July 01, 2020 , ... Psilera Bioscience ... psychedelics and analogues, announces its core executive team. The co-founders Drs. Jackie Salm ... novel formulations, and as distinguished researchers within the cannabis industry. They are joined ...
(Date:6/28/2020)... (PRWEB) , ... June 26, 2020 , ... PathAI, a ... the results of an exploratory analysis of digital scoring of PD-L1 expression to assess ... a poster #2017 at the 2020 American Association for Cancer Research (AACR) Annual Meeting. ...
(Date:6/28/2020)... ... June 28, 2020 , ... ... the world, dedicates World Allergy Week, from June 28 to July 4, 2020, ... SARS CoV-2. , COVID-19, short for “coronavirus disease 2019”, is a disease spreading ...
Breaking Medicine News(10 mins):
(Date:7/7/2020)... ... July 07, 2020 , ... Nonprofit Team PHenomenal Hope (Team PH) will announce ... its first ever virtual research town hall on Saturday, July 11 at noon EST. ... latest research in the area of pulmonary hypertension (PH), in focused talks geared toward ...
(Date:7/7/2020)... ... July 07, 2020 , ... Halifax-based startup, ... as a hair service provider. Now called Bright, the company has launched a ... offering includes beauty amenities as well as an array of well-being services that ...
(Date:7/2/2020)... ... July 02, 2020 , ... Exercise.com, the fitness industry’s leading tech company specializing ... were logged through its software during the months of May and June. This announcement ... an age where even gym giants like 24 Hour Fitness and ...
Breaking Medicine Technology:
Cached News: